Showing results (2171-2180 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 31, 2002
A phase II study of caelyx (liposomal doxorubicin) in metastatic carcinoma of the prostate: tolerability and efficacy modification by liposomal encapsulationRhona McMenemin, Graham Macdonald, Leslie Moffat, et al.
Investigational New Drugs|August 31, 2002
A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancerDavid I Rosenthal, Sue S Yom, Li Liu, et al.
Investigational New Drugs|November 27, 2002
Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? A Southwest Oncology Group studyCary A Presant, Joth Jacobson, Walter Wolf, et al.
Investigational New Drugs|November 27, 2002
Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group studyAgustin A Garcia, Michael A Bookman, Lorna Rodriguez-Rodriguez, et al.
Investigational New Drugs|November 27, 2002
A randomized phase II study of two schedules of bryostatin-1 (NSC339555) in patients with advanced malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group studyR G Tozer, S Burdette-Radoux, K Berlanger, et al.
Investigational New Drugs|November 27, 2002
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancerCynthia G Leichman, Kari Chansky, John S Macdonald, et al.
Investigational New Drugs|November 27, 2002
Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology GroupBruce J Roth, Judith Manola, Robert Dreicer, et al.
Investigational New Drugs|November 27, 2002
Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials GroupIan Quirt, Audley Bodurth, Reinhard Lohmann, et al.
Investigational New Drugs|May 11, 2002
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in renal cell cancerKeith M Skubitz
Investigational New Drugs|May 11, 2002
Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology GroupG Thomas Budd, Cathryn Rankin, Laura F Hutchins, et al.
Pageof 372